Archive for the ‘Gene Therapy Research’ Category

May #39;s Musings on Pony Genetics
Mostly just an excuse for me to reread my genetics textbook and wish I #39;d gone into that field more. XD This is the video I #39;ve been trying to get done for awh...

By: MayBpony

Read more here:
May's Musings on Pony Genetics - Video

closing to genetics project

By: haley ballard

Read this article:
closing to genetics project - Video

Stem Cell Therapy Worldwide
http://www.placidway.com/ - Looking for best and affordable stem cell therapy? Placidway offers best and most affordable stem cell therapy with the top docto...

By: placidways #39;s channel

More here:
Stem Cell Therapy Worldwide - Video

LaViv stem cell therapy for acne scars
Dermatologist and cosmetic surgeon Dr. Melanie Palm of http://www.artofskinmd.com discusses and demonstrates the use of LaVIV, the first available personalized stem...

By: melaniepalm

Read more:
LaViv stem cell therapy for acne scars - Video

Invasive procedures for removing non-melanoma skin cancers such as freezing or surgery may soon be a thing of the past.

A Queensland researcher may have found a new, less invasive way to treat the disease, which affects approximately 133,100* people in the state each year.

Dr Graham Leggatt of The University of Queensland Diamantina Institute, based at Translational Research Institute, is investigating anti-cancer immune cells as an alternative therapeutic option for non-melanoma skin cancer.

His work is being supported by a $100,000 Cancer Council Queensland research grant.

Dr Leggatt is thrilled with the announcement.

"Thanks to the support of Cancer Council Queensland, we will now be able to establish the role of immune cell therapy in clearing advanced non-melanoma skin cancers," he said.

Cancer Council Queensland CEO Professor Jeff Dunn congratulated Dr Leggatt and The University of Queensland Diamantina Institute for looking for new ways to treat non-melanoma skin cancers.

This research is particularly relevant in our country, and here in Queensland, where we have the highest rates of skin cancer in the world, he said.

As a result, non-melanoma skin cancer, which includes both squamous cell carcinoma and basal cell carcinoma, is the most commonly diagnosed cancer in Australia with approximately two per cent of the population treated for the cancer in 2002.

Current methods for treatment can be physically invasive and leave scarring. A gentler, less-invasive method of treatment would be beneficial for the long-term physical and mental recovery of the patient.

Original post:
Cell therapy to fight skin cancer

(MENAFN - AFP) Italian lawmakers on Wednesday gave their final approval to a law that allows limited use of a controversial type of stem cell therapy which has been condemned by many scientists but has given hope to families of terminally-ill children.

The law gives the go-ahead for therapy being carried out by the Stamina Foundation on dozens of patients to continue, and allows for an 18-month period of clinical trials for the procedure, which had previously been blocked by Italian authorities.

The bill was amended from an earlier version and states the therapy must be carried out under regulatory oversight and using cells made according to the Good Manufacturing Practice (GMP) which the Stamina Foundation has not adhered to.

The Stamina Foundation says its treatment is based on mesenchymal stem cells and could treat diseases like spinal cord injury and motor neurone disease.

But leading scientists have warned that there is no evidence to suggest the treatment could work and no way to know that it will not cause harm.

Patients lobbied for the therapy to be given the go-ahead, receiving support from various celebrities including actress Gina Lollobrigida.

At one demonstration, protesters wore T-shirts with the slogan: "Yes to Stamina, Yes to Life".

The association Stem Cell Research Italy has branded the new law as "unacceptable" saying the therapy was not backed up by clinical data published in peer-reviewed academic journals.

US journal Nature said it was a "rogue" therapy.

Read the rest here:
Italy approves controversial stem cell therapy

Javascript is currently disabled in your web browser. For full site functionality, it is necessary to enable Javascript. In order to enable it, please see these instructions. May 20, 2013 by Evan Lerner This is an illustration of a single-stranded DNA homopolymer translocating through a silicon nitride nanopore. The thickness of the membrane tapers within the nanopore, enhancing its sensitivity. Credit: University of Pennsylvania

(Phys.org) The allure of personalized medicine has made new, more efficient ways of sequencing genes a top research priority. One promising technique involves reading DNA bases using changes in electrical current as they are threaded through a nanoscopic hole.

Now, a team led by University of Pennsylvania physicists has used solid-state nanopores to differentiate single-stranded DNA molecules containing sequences of a single repeating base.

The study was led by Marija Drndi, an associate professor in the Department of Physics and Astronomy in the School of Arts and Sciences, along with graduate students Kimberly Venta and Matthew Puster and post-doctoral researchers Gabriel Shemer, Julio A. Rodriguez-Manzo and Adrian Balan. They collaborated with assistant professor Jacob K. Rosenstein of Brown University and professor Kenneth L. Shepard of Columbia University.

Their results were published in the journal ACS Nano.

In this technique, known as DNA translocation measurements, strands of DNA in a salt solution are driven through an opening in a membrane by an applied electric field. As each base of the strand passes through the pore, it blocks some ions from passing through at the same time; amplifiers attached to the nanopore chip can register the resulting drop in electrical current. Because each base has a different size, researchers hope to use this data to infer the order of the bases as the strand passes through. The differences in base sizes are so small, however, that the proportions of both the nanopores and membranes need to be close those of the DNA strands themselvesa major challenge.

The nanopore devices closest to being a commercially viable option for sequencing are made out of protein pores and lipid bilayers. Such protein pores have desirable proportions, but the lipid bilayer membranes in which they are inserted are akin to a film of soap, which leaves much to be desired in terms of durability and robustness.

Solid-state nanopore devices, which are made of thin solid-state membranes, offer advantages over their biological counterpartsthey can be more easily shipped and integrated with other electronicsbut the basic demonstrations of proof-of-principle sensitivity to different DNA bases have been slower.

"While biological nanopores have shown the ability to resolve single nucleotides, solid-state alternatives have lagged due to two challenges of actually manufacturing the right-sized pores and achieving high-signal, low-noise and high-bandwidth measurements," Drndi said. "We're attacking those two challenges here."

Because the mechanism by which the nanopore differentiate between one type of base and another is by the amount of the pore's aperture that is blocked, the smaller a pore's diameter, the more accurate it is. For the nanopore to be effective at determining a sequence of bases, its diameter must approach the diameter of the DNA and its thickness must approach that of the space between one base and the next, or about 0.3 nanometers.

Go here to read the rest:
Advance in nanotech gene sequencing technique

May 23, 2013

Brett Smith for redOrbit.com Your Universe Online

Geneticists at theMedical College of Georgia at Georgia Regents University have identified a key regulatory gene that appears to play a role in the classic symptoms of schizophrenia.

According to a report in thejournalNeuron on the discovery targets expression of a gene known as Neuregulin-1 and could lead to promising treatments for patients with the psychological disorder.

In the study, the geneticists engineered mice to have elevated levels of Neuregulin-1 activity, replicating levels found in some patients diagnosed with schizophrenia. They observed the reduced activity of the brain messengers glutamate and GABA, a major inhibitory neurotransmitter. These mice were also seen to interact less with other animals and frequently failed certain thinking tasks, behaviors also seen in humans with schizophrenia.

The deficits reversed when we normalized Neuregulin-1 expression in animals that had been symptomatic, suggesting that damage which occurred during development is recoverable in adulthood, explained Dr. Lin Mei, a professor at the university.

While mouse models cant really do full justice to a complex brain disorder that impairs our most uniquely human characteristics, this study demonstrates the potential of dissecting the workings of intermediate components of disorders in animals to discover underlying mechanisms and new treatment targets, said Dr. Thomas R. Insel, a director at the National Institutes of Health, which funded the study.

Hopeful news about how an illness process that originates early in development might be reversible in adulthood illustrates the promise of such translational research.

The geneticists were able to measure Neuregulin-1 activity fairly easily, as blood level indicators correlate well with those in the brain. To affect the mice, the researchers put a copy of the Neureglin-1 gene into mouse DNA. In front of that gene the team put a binding protein for doxycycline, an analogue for the antibiotic tetracycline, which stains the teeth of fetuses and babies. This causes the administration of tetracycline to result in a drop in Neureglin-1 activity.

If you dont feed the mice tetracycline, the Neuregulin-1 levels are always high, said Mei, adding that normal levels of the gene are not affected by the antibiotic.

Read more here:
Controlling Schizophrenia Gene Could Help Tame The Disease

Public release date: 23-May-2013 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, May 23, 2013Detection of HIV antibodies is used to diagnose HIV infection and monitor trials of experimental HIV/AIDS vaccines. New, more sensitive detection systems being developed use microspheres to capture HIV antibodies and can measure even small amounts of multiple antibodies at one time. This novel multiplex immunoassay approach is described in an article in BioResearch Open Access, a peer-reviewed open access journal from Mary Ann Liebert, Inc., publishers (http://www.liebertpub.com). The article is available on the BioResearch Open Access website (http://www.liebertpub.com/biores).

The ability to detect very low levels of HIV virus is critical for early detection of HIV infection and to assess the effectiveness of an AIDS vaccine. Rebecca L.R. Powell and coauthors from the International AIDS Vaccine Initiative, Brooklyn, NY, compared the microsphere-based BioPlex Suspension Array System to conventional ELISA antibody test methods for detecting simian immunodeficiency virus (SIV) in SIV-infected rhesus macaques.

The specificity of the two methods were comparable. The microsphere-based test system successfully detected four key HIV antibodies simultaneously in SIV-infected animals, compared to noninfected control animals. Furthermore, in blood samples that tested negative for one or more HIV antibody using an ELISA test, the microsphere assay was often able to detect the antibody in the sample.

The findings were presented in the article "A Multiplex Microsphere-Based Immunoassay Increases the Sensitivity of SIV-Specific Antibody Detection in Serum Samples and Mucosal Specimens Collected from Rhesus Macaques Infected with SIVmac239." (http://online.liebertpub.com/doi/full/10.1089/biores.2013.0009)

"This new method provides a significant improvement over standard ELISA techniques, allowing increased sensitivity for specific antibody detectionwhich is highly important for assessing vaccine efficacy," says BioResearch Open Access Editor Jane Taylor, PhD, MRC Centre for Regenerative Medicine, University of Edinburgh, Scotland.

###

About the Journal

BioResearch Open Access is a bimonthly peer-reviewed open access journal led by Editor-in-Chief Robert Lanza, MD, Chief Scientific Officer, Advanced Cell Technology, Inc. and Editor Jane Taylor, PhD. The Journal provides a new rapid-publication forum for a broad range of scientific topics including molecular and cellular biology, tissue engineering and biomaterials, bioengineering, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience. All articles are published within 4 weeks of acceptance and are fully open access and posted on PubMedCentral. All journal content is available on the BioResearch Open Access website (http://www.liebertpub.com/biores).

Excerpt from:
New microsphere-based methods for detecting HIV antibodies

If you want to keep your DNA to yourself, be sure not to leave any stray hairs, Q-tips or underwear lying around. There are genetic testing companies out there willing to reveal your most intimate biological secrets to anybody -- without your knowledge or permission.

And under California law, such genetic snooping is perfectly legal.

Now, legislators in Sacramento are considering a bill to change that. Senate Bill 222, which faces a key hearing Thursday, would require a donor's consent to collect, analyze or share genetic information. While the legislation might seem like a slam-dunk in the ever-evolving battle between technology and privacy, it's generating opposition from unlikely quarters: major research universities such as Stanford and the University of California, which argue that providing those protections will create unnecessary red tape and costs.

"We have privacy laws in place to protect health and financial information," said the bill's author, Alex Padilla, D-Pacoima. "But arguably the most personal information about us -- our own genetic profile -- isn't protected."

Most Californians are probably familiar with genetic testing companies such as 23AndMe that will screen customers' DNA for their predisposition to cancer, diabetes, Parkinson's, Alzheimer's and a host of other diseases. But less known is that a growing number of firms are also offering paternity testing -- with or without a person's knowledge -- as well as

Padilla cites Elk Grove-based EasyDNA, which makes no attempt on its website to discourage customers from secretly sending in someone else's genetic material under its "discreet DNA samples" program.

"Sometimes it is not possible to directly obtain samples from the person who needs to be tested," says the website. "In this case, discreet samples can be submitted instead. Samples that can be used include strands of hair, blood, clothing, cigarette butts and other items that may contain traces of DNA."

EasyDNA representatives did not return repeated phone calls.

Mountain View-based 23AndMe says it has an extensive privacy policy in place -- and that the company doesn't do paternity or infidelity testing.

"We require that the person who's submitting the sample is the person who has legal authorization or consent on behalf of the person they're providing samples for," said 23AndMe spokeswoman Catherine Afarian.

See the original post:
Bill would prevent genetic-testing firms from using surreptitiously obtained DNA

If you want to keep your DNA to yourself, be sure not to leave any stray hairs, Q-tips or underwear lying around. There are genetic testing companies out there willing to reveal your most intimate biological secrets to anybody -- without your knowledge or permission.

And under California law, such genetic snooping is perfectly legal.

Now, legislators in Sacramento are considering a bill to change that. Senate Bill 222, which faces a key hearing Thursday, would require a donor's consent to collect, analyze or share genetic information. While the legislation might seem like a slam-dunk in the ever-evolving battle between technology and privacy, it's generating opposition from unlikely quarters: major research universities such as Stanford and the University of California, which argue that providing those protections will create unnecessary red tape and costs.

"We have privacy laws in place to protect health and financial information," said the bill's author, Alex Padilla, D-Pacoima. "But arguably the most personal information about us -- our own genetic profile -- isn't protected."

Most Californians are probably familiar with genetic testing companies such as 23AndMe that will screen customers' DNA for their predisposition to cancer, diabetes, Parkinson's, Alzheimer's and a host of other diseases. But less known is that a growing number of firms are also offering paternity testing -- with or without a person's knowledge -- as well as

Padilla cites Elk Grove-based EasyDNA, which makes no attempt on its website to discourage customers from secretly sending in someone else's genetic material under its "discreet DNA samples" program.

"Sometimes it is not possible to directly obtain samples from the person who needs to be tested," says the website. "In this case, discreet samples can be submitted instead. Samples that can be used include strands of hair, blood, clothing, cigarette butts and other items that may contain traces of DNA."

EasyDNA representatives did not return repeated phone calls.

Mountain View-based 23AndMe says it has an extensive privacy policy in place -- and that the company doesn't do paternity or infidelity testing.

"We require that the person who's submitting the sample is the person who has legal authorization or consent on behalf of the person they're providing samples for," said 23AndMe spokeswoman Catherine Afarian.

Continue reading here:
California bill would prevent genetic-testing firms from using surreptitiously obtained DNA

May 23, 2013

Lee Rannals for redOrbit.com Your Universe Online

A new technique featured in the Journal of Visualized Experiments (JoVE) could lead to the development of a genetic thermometer that could assess a patients health in relation to other individuals.

The method developed by the laboratory of Dr. Gil Atzmon at New Yorks Albert Einstein College of Medicine measures telomere length, which serve as the caps to chromosomes. Telomeres mark the ends of genetic material and ensure that genes do not degrade as cells divide.

Think of telomere length as though it was a thermometer. It measures the health of your genetic material, Dr. Atzmon explains. It tells you how fit you are in relation to the age you are. If you have longer telomeres you are in good shape, if you have shorter telomeres you are less fit for your age and are not in good health.

Telomerase activity eclipses as people age, and as a result telomeres shorten and can be responsible for age related afflictions and some cancers. An individuals overall health can impact how quickly these telomeres degrade.

Telomere length and telomerase function impacts several realms of biological and medical research- from preventative aging models to cancer treatments. Maintaining the telomere is a pre-requisite to extending life and improving long-term health, said Dr. Kira Henderson, JoVE Editor and Director of Review.

JoVE films and edits videos of researchers performing new experimental techniques to allow students and scientists to learn them quickly. The journal has published video-protocols from an international community of over 8,000 authors in the fields of biology, medicine, chemistry and physics.

I published in JoVE because I want more people to use the technique. As we [the medical community] collect more data, we can build a better index of age and health by population, and more accurately place a patient on the right spot in a continuum, said Dr. Atzmon. He added that he hopes the publication will impact the aging community by classifying health relative to an individuals age.

Henderson hopes the research teams JoVE video-article will elucidate relationships between disease state and telomere function.

Follow this link:
Measuring The Health Of Human Genetic Material In Relation To A Patient's Age

Public release date: 23-May-2013 [ | E-mail | Share ]

Contact: Bruce Goldman goldmanb@stanford.edu 650-725-2106 Stanford University Medical Center

STANFORD, Calif. - Ethnic background plays a surprisingly large role in how diabetes develops on a cellular level, according to two new studies led by researchers at the Stanford University School of Medicine.

The researchers reanalyzed disease data to demonstrate that the physiological pathways to diabetes vary between Africa and East Asia and that those differences are reflected in part by genetic differences. The studies will be published online simultaneously May 23 in the journals PLoS Genetics and Diabetes Care.

"We have new insights into the differences in diabetes across the world, just by this new perspective applied to older studies," said Atul Butte, MD, PhD, senior author of the studies and chief of the Division of Systems Medicine and associate professor of pediatrics and of genetics. "There's more still to learn about diabetes than we knew."

The early stages of type-2 diabetes, or adult-onset diabetes, can develop when the pancreas has problems creating sufficient insulin, a hormone critical for regulating blood sugar, or when the body's cells have trouble responding to insulin, a condition called "insulin resistance." Both problems will lead to the same result: too much sugar in a person's blood stream, which is the main criterion for diagnosing diabetes. Diabetics develop both low insulin secretion and insulin resistance as the disease progresses.

In the study to be published in PLoS Genetics, the researchers started by studying genome information of more than 1,000 people in 51 populations from around the world. These individuals were from indigenous populations, representing the earliest groups of humans at various locations. Lead author and former graduate student in Butte's lab, Erik Corona, PhD, studied more than 100 diseases searching for genetic differences in risk across these native populations, and found a clear geographic pattern in the genetics behind type-2 diabetes. The genetic risk is highest for Africans and drops along the trajectory the first humans took when migrating out of Africa toward East Asia (primarily Japan, China and Korea), where diabetes-linked genes appear to be more protective. Based solely on what is currently known about type-2 diabetes genetics, native Africans would appear to be at higher risk for diabetes, while East Asians would appear to be protected. But East Asians are not necessarily at lower risk of diabetes than Africans. Butte pointed out that "East Asians definitely get diabetes. What we would argue is that diabetes may be a different disease" in East Asian populations. An interactive tool that displays the results can be found at http://geneworld.stanford.edu/hgdp.html.

The genetics study's findings led Butte's team to wonder if there was clinical evidence of these differences in African and East Asian populations. For the second paper, lead author and staff engineering research associate Keiichi Kodama, MD, PhD, pulled data from more than 70 papers looking at simultaneously measured insulin secretion and insulin resistance in individuals across three different ethnic groups: Africans, Caucasians and East Asians. They found that at baseline, Africans had higher insulin resistance but were able to compensate with higher insulin secretion. East Asians were more likely to have less insulin-secretion ability, but this was compensated by having normal insulin resistance. Caucasians fell between these two groups, though they were more likely to develop problems with insulin secretion.

The researchers showed that because individuals from each ethnic group start at a different baseline position, they each reach diabetes in a different way: Africans through increased insulin resistance, and East Asians through lower insulin-secretion ability. "Africans are already pretty insulin resistant," Butte said. "They need their beta cells to work really hard. If their cells fail, that's how they head toward diabetes." East Asians, in contrast, "don't have a lot of spare capacity to secrete more insulin." The findings will be published in Diabetes Care.

Butte notes that a shift in how clinicians think about diabetes could lead to more targeted therapies, much as how thinking about cancer has evolved over the past 10 years, leading to new treatments. "Other fields of medicine have undergone a radical rethinking in disease taxonomy, but this has not happened yet for diabetes, one of the world's public health menaces," he said. "If these are separate diseases at a molecular level, we need to try to understand that."

More:
Diabetes' genetic underpinnings can vary based on ethnic background, Stanford studies say

Kenneth Miller Evolution Creation Genetics Christian Atheist The Collapse of Intelligent Design 7

By: Secrets ~ Mysteries ~ Conspiracies

Continue reading here:
Kenneth Miller Evolution Creation Genetics Christian Atheist The Collapse of Intelligent Design 7 - Video

Kenneth Miller Evolution Creation Genetics Christian Atheist The Collapse of Intelligent Design 5

By: Secrets ~ Mysteries ~ Conspiracies

Link:
Kenneth Miller Evolution Creation Genetics Christian Atheist The Collapse of Intelligent Design 5 - Video

Kenneth Miller Evolution Creation Genetics Christian Atheist The Collapse of Intelligent Design 6

By: Secrets ~ Mysteries ~ Conspiracies

Visit link:
Kenneth Miller Evolution Creation Genetics Christian Atheist The Collapse of Intelligent Design 6 - Video

Kenneth Miller Evolution Creation Genetics Christian Atheist The Collapse of Intelligent Design 8

By: Secrets ~ Mysteries ~ Conspiracies

Read more from the original source:
Kenneth Miller Evolution Creation Genetics Christian Atheist The Collapse of Intelligent Design 8 - Video

Kenneth Miller Evolution Creation Genetics Christian Atheist The Collapse of Intelligent Design 2

By: Secrets ~ Mysteries ~ Conspiracies

Read more here:
Kenneth Miller Evolution Creation Genetics Christian Atheist The Collapse of Intelligent Design 2 - Video

Genetics and Ethics
This is a science project we had about "Genetics and Ethics." Included is a movie trailer and featurettes.

By: Skye Yoo

See the original post here:
Genetics and Ethics - Video

SC.7.L.16.1. Alien Genetics
Students will learn about genetics, DNA, genes, and dominant and recessive traits. Florida Sunshine State Standard SC.7.L.16.1: Understand and explain that every organism requires a set of...

By: SUMMITucf

Excerpt from:
SC.7.L.16.1. Alien Genetics - Video

Generator divine genetics Generator existence, light, truth, PUBLIC
http://www.wuala.com/esgseis 309 people killed in 2009 by mafia 666 from Italy Israel Romania! Ministry of Defence at murder, secret, lies, genocide, prison intellectual, homo sapiens, with...

By: Nmeilis Nmeinis

Read the rest here:
Generator divine genetics Generator existence, light, truth, PUBLIC - Video

Angelina Jolie #39;s Mastectomy: Patenting Genes is Patenting a Discovery
Newsclick discusses with Satyajit Rath from the National Institute of Immunology the issue of Gene Patenting, in the background of Angelina Jolie #39;s mastectom...

By: http://newsclick.in

Read more:
Angelina Jolie's Mastectomy: Patenting Genes is Patenting a Discovery - Video

RUTHERFORD, N.J.--(BUSINESS WIRE)--

Cancer Genetics, Inc. (CGIX) ("CGI" or the "Company"), an emerging leader in DNA-based cancer diagnostics, will present at the second annual Marcum MicroCap Conference on Thursday, May 30, 2013 at 2:30 p.m. ET at the Grand Hyatt New York in New York City.

The Marcum MicroCap Conference is dedicated to introducing investors to the best undiscovered companies under $500 million in market capitalization. In addition, the conference will showcase a number of panels that discuss issues that are of vital importance to small cap issuers and investors. The conference is expected to draw more than 1,000 attendees, including senior personnel from over 100 presenting public companies, leading institutional investors, directors, bankers and service providers to the microcap marketplace.

To learn more about the Marcum MicroCap Conference, visit http://marcumllp.com/MicroCap.

About Cancer Genetics, Inc.

Cancer Genetics, Inc. (CGI) is an emerging leader in DNA-based cancer diagnostics and servicessome of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. CGI has established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic and the National Cancer Institute. For further information, please seewww.cancergenetics.com.

View original post here:
Cancer Genetics to Present at Marcum MicroCap Conference

SEATTLE, WA--(Marketwired - May 23, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company, will display its ForeCYTE Breast Health Test at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, from May 31 through June 4, 2013. Atossa's exhibit will be located in booth 2019 at McCormick Place.

The ForeCYTE Breast Health Test, developed and marketed by Atossa Genetics, detects reversible precancerous conditions in the breast up to eight years before they become cancer. The test uses a hand-held, FDA Class II medical device that is quick, painless, and non-invasive and can be administered during an OB/GYN office visit. Unlike mammograms, which are commonly recommended for women starting at age 40 to 50, the ForeCYTE Breast Health Test is more age agnostic, uses no radiation and does not require invasive biopsy needles or surgical incisions. To view a video about the ForeCYTE Test, click here: https://vimeo.com/62365818.

"We believe that our ForeCYTE Breast Health Test represents a breakthrough in breast cancer risk assessment testing. The ForeCYTE test can provide vital early detection of cancer or precancerous conditions and therefore help prevent breast cancer and save lives. We look forward to presenting the ForeCYTE test's value at ASCO, the largest gathering of oncologists in the nation," said Chris Destro, Vice President of Atossa, who will attend the exhibition.

Atossa's ForeCYTE Breast Health Test is available through physicians nationwide.

About the ASCO Annual Meeting

The ASCO annual meeting brings together more than 25,000 oncology professionals from a broad range of specialties, making an excellent venue for exploring the theme of the Meeting -- "Building Bridges to Conquer Cancer."

About Atossa Genetics, Inc.

Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company, based in Seattle, WA, is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography.

The National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington.

For additional information on Atossa and the ForeCYTE test, please visit http://www.atossagenetics.com.

Continued here:
Atossa Genetics to Exhibit Its ForeCYTE Breast Health Test at the 2013 ASCO Annual Meeting

WALTHAM, Mass.--(BUSINESS WIRE)--

Interleukin Genetics, Inc. (ILIU) will host a conference call and Webcast today at 4:30 p.m. (EDT) to provide a corporate update and discuss the Companys first quarter results.

As reported previously this week, Interleukin has raised $12 million through a private placement of its securities. The financing was comprised of new investors led by Bay City Capital with participation from NEA and Merlin Nexus. Dayton Misfeldt and Lionel Carnot, Investment Partners at Bay City Capital, have joined Interleukins Board of Directors.

We are excited to support Interleukin Genetics in the commercialization of its PST genetic test for periodontal disease susceptibility, said Dayton Misfeldt. Important new scientific evidence emerging on the value of the IL-1 genetic test for periodontitis risk should enable Interleukin to widely distribute the PST test and its personalized health approach to dentistry which will assist dentists in providing the care their patients need, added Lionel Carnot.

Interleukin Genetics intends to use the net proceeds from the private placement primarily to move its currently validated molecular diagnostic tests, most immediately the test for predicting periodontitis progression and severity(PST), into broad commercialization.

We are very pleased to have the support of outstanding life science investors such as Bay City Capital, NEA, and Merlin, said Dr. Kenneth Kornman, Chief Executive Officer of Interleukin Genetics. The new financing will allow us to rapidly move to commercialize the emerging evidence that shows the value of PST in guiding better oral health and the optimal use of preventive resources for adult periodontitis, one of the most common chronic diseases of aging.

Conference Call Information

Interleukin will host a conference call and Webcast today at 4:30 p.m. (EDT) to provide a corporate update and discuss the Companys first quarter results. To access the live call, dial 877-324-1976 (domestic) or 631-291-4550 (international). The live Webcast and replay access of the teleconference will be available on the Investors section of Interleukin Genetics, Inc.s Website at http://www.ilgenetics.com.

About Interleukin Genetics, Inc.

Interleukin Genetics, Inc. (ILIU) develops and markets a line of genetic tests under the Inherent Health and PST brands.The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics flagship products include its proprietary PST genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, Mass. and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit http://www.ilgenetics.com.

Link:
Interleukin Genetics to Discuss Corporate Update and First Quarter Results